Volume 38,
Issue 12,
2017
-
Topics:心臓にやさしいご当地レシピ 秋田編
-
-
Source:
Therapeutic Research 38巻12号, 1175-1179 (2017);
View Description
Hide Description
-
Symposium:第22回日本神経精神医学会
-
-
特別講演
-
Source:
Therapeutic Research 38巻12号, 1187-1190 (2017);
View Description
Hide Description
-
総説
-
-
Source:
Therapeutic Research 38巻12号, 1205-1216 (2017);
View Description
Hide Description
長時間作用性抗コリン薬のチオトロピウムは,気道平滑筋のムスカリン受容体への拮抗作用を介して気管支拡張作用を示す。わが国ではチオトロピウムのソフトミスト製剤(スピリーバ(R) レスピマット(R))が2014 年に重症持続型の喘息患者に対して認可され,2016 年にすべての重症度の気管支喘息へ適応が拡大された。本剤の喘息に対する有効性および安全性を評価する臨床開発プログラムであるUniTinA‒asthma(R)では,6000 名以上の患者を対象とした計18 の試験(第Ⅱ相7 試験,第Ⅲ相11 試験)から構成され,全重症度を網羅し小児(1~17 歳)から成人まで幅広い年齢層を対象とした第Ⅲ相試験の結果が報告されている。本総説では,Uni-TinA‒asthma(R) 第Ⅲ相試験の結果を概説するとともに,チオトロピウムの喘息に対する有効性,安全性,臨床的な特徴を紹介する。
-
Source:
Therapeutic Research 38巻12号, 1217-1230 (2017);
View Description
Hide Description
-
原著
-
-
Source:
Therapeutic Research 38巻12号, 1231-1237 (2017);
View Description
Hide Description
Objectives:High‒dose of metformin was approved in 2010 and fixed dose combination of metformin and DPP‒4 inhibitor(DPP4i)was launched in 2016, thus diversifying the usage of metformin. In this report, the actual usage status of metformin and DPP‒4i was investigated in patients with type 2 diabetes. Methods:Using prescription data from the Japan Medical Data Center, patients were classified into three groups which were comprised all patients who were prescribed metformin(whole group), patients prescribed metformin alone(Met‒alone group)and patients prescribed a combination of metformin and DPP‒4i (combination group). The actual status of metformin and DDP‒4i prescription was analyzed in these groups. Results:The proportion of young patients tended to be higher in Met‒alone group than in the whole group and the combination group. DPP‒4i was co‒administered with metformin in 66‒67% of patients in all groups. The mean daily dosage of metformin in the Met‒alone group(792.8 mg) was relatively low compared with that in the whole group(916.4 mg)and the combination group(928.9 mg). Metformin was administered twice daily at 250 or 500 mg/day in most patients in all groups. Conclusions:In this observation, it was indicated that metformin was administered at 500 or 750<‒1000 mg/day in most patients. It was also shown that combined medication with metformin and DPP‒4i was the leading therapy for oral medication in patients with type 2 diabetes. Additional studies are needed to clarify the usage status of metformin and DPP4i by patient background such as comorbidity and body mass index.
-
INFORMATION
-
-
Source:
Therapeutic Research 38巻12号, 1239-1241 (2017);
View Description
Hide Description